Aelis Farma reports positive retrospective study results for AEF0217 in Down syndrome

Aelis Farma announced positive results from a retrospective study evaluating its drug candidate AEF0217 in patients with Down syndrome, suggesting the clinical effects translate into meaningful improvements in real-life functioning. The results highlight the potential of its CB1-SSi platform in addressing cognitive disorders.

Detected & updated continuously · Source: Nebula